Latest Biotech News

Ocugen reported interim Phase 2 data for its geographic atrophy gene therapy program showing positive signals from a limited patient cohort. Company statements said the candidate demonstrated...

Oxford Biomedica, a major contract manufacturer for cell and gene therapies, confirmed takeover talks with private equity investor EQT after rejecting multiple bids it deemed to undervalue the...

BloodPAC published standardized analytical-validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays, setting a common blueprint for how companies should demonstrate limit of...

Johnson & Johnson reported Phase 3 results showing Tecvayli reduced risk of disease progression or death versus standard regimens in patients who relapsed after frontline therapy, with the company...

NVIDIA and Eli Lilly announced a five‑year, $1 billion co‑innovation lab to deploy large‑scale AI computing and models for drug discovery, signaling a major industry pivot to tightly integrated...

Boston Scientific agreed to acquire Penumbra for about $14.5 billion in cash and stock, a deal that would add Penumbra’s thrombectomy and embolization platforms to Boston Scientific’s...

Oxford Biomedica, a major contract‑manufacturer for cell and gene therapy, confirmed it has engaged in takeover talks with private equity investor EQT after turning down prior unsolicited bids the...

Cellares signed a long‑term lease at Leiden Bio Science Park for a new Integrated Development and Manufacturing Organization (IDMO) Smart Factory that will serve as the company’s European...

The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million / ~$857 million) to the BioInnovation Institute (BII) to expand operations, increase the number of startups supported...

Caldera Therapeutics emerged from stealth with $112.5 million in combined Series A and A‑1 financing to advance CLD‑423, a dual‑targeting bispecific licensed from China’s Qyuns Therapeutics for...

Scribe Therapeutics, a company developing therapeutics based on novel CRISPR enzymes, said it plans to begin testing its first gene‑editing therapy in the clinic this summer. The program...

Illumina launched the Billion Cell Atlas, an initial installment of a planned five‑billion‑cell genetic perturbation dataset built in partnership with AstraZeneca, Merck and Eli Lilly, intended to...

Boston Scientific announced an agreement to acquire Penumbra for about $14.5 billion, a transaction aimed at expanding Boston Scientific’s presence in thrombectomy and embolization markets....

NVIDIA and Eli Lilly unveiled a five-year, $1 billion collaboration to build an AI co‑innovation lab focused on drug discovery, committing compute and model development to accelerate in‑silico...

The Blood Profiling Atlas in Cancer (BloodPAC) consortium published generic protocols for analytical validation of tumor‑informed circulating tumor DNA (ctDNA) assays for minimal residual disease...

Cellares signed a long‑term lease for a Smart Factory at Leiden Bio Science Park that will serve as the company’s European headquarters and regional integrated development and manufacturing...

Johnson & Johnson reported positive Phase 3 survival outcomes for Tecvayli (teclistamab) in an earlier‑line multiple myeloma setting, supporting the drugmaker’s strategy to expand use beyond later...

Natera told investors that Signatera drove record growth and will remain a revenue engine in 2026, with Q4 being the company’s fastest‑growing quarter for the MRD test. Management flagged expected...

Eli Lilly said the FDA is expected to decide on its oral obesity pill orforglipron in the second quarter of 2026 after granting Lilly a national priority review voucher intended to accelerate...

Illumina released the first installment of its Billion Cell Atlas, a genome‑wide genetic perturbation dataset designed to train AI models for drug discovery. Illumina named AstraZeneca, Merck and...